TORONTO, ONTARIO, Nov. 10, 2023 (GLOBE NEWSWIRE) -- (“Amaroq” or the “Company”) Block Listing Six Monthly Return TORONTO, ONTARIO – November 10, 2023 – Amaroq Minerals Ltd. (AIM, TSXV, NASDAQ First North: AMRQ), an independent mine development company with …
Wilmington, Delaware, United States, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Transparency Market Research Inc. - The global waterborne coatings market was estimated at a value of US$ 79.1 billion in 2022. It is anticipated to register a 5.8% CAGR from 2023 to …
Addressing the Urgent Need for Advanced Cancer Care and Education in the Region BRISTOL, NORTH SOMERSET, UNITED KINGDOM, November 10, 2023 /EINPresswire.com/ -- Stepping into the forefront of healthcare advancements in Latin America, Lacort …
NEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of PacWest Bancorp (NASDAQ: PACW, PACWP) between February 28, 2022 and May 3, 2023, both dates inclusive (the “Class Period …
JACKSON, MISSISSIPPI, UNITED STATES, November 10, 2023 /EINPresswire.com/ -- Highland Village is gearing up for the holiday season. Today they revealed two pop-up shops that will call Highland Village home for the holidays: High-end hunting gear retailer …
American Orthodontics, a manufacturer of orthodontic supplies and products with headquarters at 3524 Washington Ave. in Sheboygan, is adding another site in Saukville. It is part of the village’s Northern Gateway Community Collective, a 99-acre development …
ATLANTA, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC informs investors that a shareholder class action lawsuit has been filed against FMC Corporation (“FMC” or the “Company”) (NYSE: FMC). The lawsuit alleges FMC made false or misleading …
NaXum, a leading innovator in creative solutions, is excited to introduce Project Phoenix. LAS VEGAS, NEVADA, UNITED STATES, November 10, 2023 /EINPresswire.com/ -- NaXum, a leading innovator in creative solutions, is thrilled to unveil Project Phoenix …
For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Keytruda. The marketing authorisation holder for this …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Pradaxa. The marketing authorisation holder for this …
For the United Kingdom, as of 1 January 2021, European Union law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland / NI.
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ayvakyt. The marketing authorisation holder for this …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Mounjaro. The marketing authorisation holder for this …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Uzprovo, intended for the treatment of plaque psoriasis, including …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Naveruclif, intended for the treatment of metastatic breast cancer, …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rystiggo1, intended for the treatment of Myasthenia Gravis (gMG). The …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Omjjara1, intended for the treatment of disease-related splenomegaly …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Spexotras1, intended for the treatment of low- and high-grade glioma …
On 9 November 2023, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for the medicinal product Rimmyrah, intended for the treatment of neovascular (wet) age-related …
01 days 16:43:46
